139 related articles for article (PubMed ID: 7693753)
1. Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis.
Piddlesden SJ; Morgan BP
J Neuroimmunol; 1993; 48(2):169-75. PubMed ID: 7693753
[TBL] [Abstract][Full Text] [Related]
2. Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59.
Wing MG; Zajicek J; Seilly DJ; Compston DA; Lachmann PJ
Immunology; 1992 May; 76(1):140-5. PubMed ID: 1378423
[TBL] [Abstract][Full Text] [Related]
3. Complement mediated serum cytotoxicity against oligodendrocytes: a comparison with other cells of the oligodendrocyte-type 2 astrocyte lineage.
Scolding NJ; Morgan BP; Campbell AK; Compston DA
J Neurol Sci; 1990 Jul; 97(2-3):155-62. PubMed ID: 2205708
[TBL] [Abstract][Full Text] [Related]
4. Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system.
Zajicek J; Wing M; Skepper J; Compston A
Lab Invest; 1995 Jul; 73(1):128-38. PubMed ID: 7541492
[TBL] [Abstract][Full Text] [Related]
5. Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes.
Gasque P; Morgan BP
Immunology; 1996 Nov; 89(3):338-47. PubMed ID: 8958045
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid concentrations of the complement MAC inhibitor CD59 in multiple sclerosis and patients with other neurological disorders.
Roddy J; Clark I; Hazleman BL; Compston DA; Scolding NJ
J Neurol; 1994 Aug; 241(9):557-60. PubMed ID: 7528270
[TBL] [Abstract][Full Text] [Related]
7. Implication of membrane factors other than DAF and CD59 in complement-mediated lysis of paroxysmal nocturnal hemoglobinuria erythrocytes.
Hatanaka M; Inai S; Matsumoto M; Miyagawa S; Masaoka T; Kanamaru A; Kawakita M; Yonemura Y; Sugita Y; Seya T
Clin Immunol Immunopathol; 1993 Oct; 69(1):52-9. PubMed ID: 7691453
[TBL] [Abstract][Full Text] [Related]
8. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.
Jurianz K; Ziegler S; Donin N; Reiter Y; Fishelson Z; Kirschfink M
Int J Cancer; 2001 Sep; 93(6):848-54. PubMed ID: 11519047
[TBL] [Abstract][Full Text] [Related]
9. The expression of complement regulatory proteins by adult human oligodendrocytes.
Scolding NJ; Morgan BP; Compston DA
J Neuroimmunol; 1998 Apr; 84(1):69-75. PubMed ID: 9600710
[TBL] [Abstract][Full Text] [Related]
10. Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies.
Scolding NJ; Morgan BP; Houston A; Campbell AK; Linington C; Compston DA
J Neurol Sci; 1989 Feb; 89(2-3):289-300. PubMed ID: 2926453
[TBL] [Abstract][Full Text] [Related]
11. Neuronal protection of oligodendrocytes from antibody-independent complement lysis.
Agoropoulou C; Piddlesden SJ; Lachmann PJ; Wing MG
Neuroreport; 1998 Mar; 9(5):927-32. PubMed ID: 9579692
[TBL] [Abstract][Full Text] [Related]
12. Reversible injury of cultured rat oligodendrocytes by complement.
Scolding NJ; Houston WA; Morgan BP; Campbell AK; Compston DA
Immunology; 1989 Aug; 67(4):441-6. PubMed ID: 2767708
[TBL] [Abstract][Full Text] [Related]
13. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
[TBL] [Abstract][Full Text] [Related]
14. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
[TBL] [Abstract][Full Text] [Related]
15. Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody.
Wren DR; Noble M
Proc Natl Acad Sci U S A; 1989 Nov; 86(22):9025-9. PubMed ID: 2813437
[TBL] [Abstract][Full Text] [Related]
16. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement.
Scolding NJ; Morgan BP; Houston WA; Linington C; Campbell AK; Compston DA
Nature; 1989 Jun; 339(6226):620-2. PubMed ID: 2733792
[TBL] [Abstract][Full Text] [Related]
17. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells.
Hakulinen J; Meri S
Lab Invest; 1994 Dec; 71(6):820-7. PubMed ID: 7528832
[TBL] [Abstract][Full Text] [Related]
18. C5b-8 step lysis of swine endothelial cells by human complement and functional feature of transfected CD59.
Miyagawa S; Mikata S; Shirakura R; Matsuda H; Nagasawa S; Terados A; Hatanaka M; Matsumoto M; Seya T
Scand J Immunol; 1996 Apr; 43(4):361-6. PubMed ID: 8668913
[TBL] [Abstract][Full Text] [Related]
19. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity.
Brasoveanu LI; Altomonte M; Gloghini A; Fonsatti E; Coral S; Gasparollo A; Montagner R; Cattarossi I; Simonelli C; Cattelan A
Int J Cancer; 1995 May; 61(4):548-56. PubMed ID: 7538980
[TBL] [Abstract][Full Text] [Related]
20. The influence of tumour necrosis factor-alpha, interleukin-1 beta and interferon-gamma on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29.
Bjørge L; Jensen TS; Ulvestad E; Vedeler CA; Matre R
Scand J Immunol; 1995 Apr; 41(4):350-6. PubMed ID: 7534941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
